Article
Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer.
The oncologist - 1 Aug 2021
Sahin Ibrahim Halil, Goyal Subir, Pumpalova Yoanna, Sonbol Mohamad B, Das Satya, Haraldsdottir Sigurdis, Ahn Daniel, Ciombor Kristen K, Chen Zhengjia, Draper Amber, Berlin Jordan, Bekaii-Saab Tanios, Lesinski Gregory B, El-Rayes Bassel F, Wu Christina
Abstract excerpt
BACKGROUND: Immune checkpoint inhibitor (ICI) therapy is highly effective in metastatic mismatch repair-deficient (MMR-D) colorectal cancer (CRC). In this study, we evaluated molecular and clinical predictors of ICI response in MMR-D CRC. MATERIALS AND METHODS: Patient databases at four cancer institutions were queried. The Fisher exact test was performed to test the association of clinical and molecular markers....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.